The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature

European Urology, 03/19/2012

The addition of sipuleucel–T, an immunotherapeutic agent, to the armamentarium represents a paradigm shift in therapy for metastatic castration–resistant prostate cancer. The rational combination and proper sequencing of sipuleucel–T with other newly approved agents and emerging agents will be important to evaluate.

Print Article Summary Cat 2 CME Report